Related Experiment Video
Updated: Jan 15, 2026
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
ALCAM-CD6 axis suppression: a key determinant of immune-mediated metastasis recurrence in stage III non-small cell
Shaodi Wen1, Xiaoyue Du1, Miaolin Zhu1
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.
Background:
Metastatic recurrence poses a significant challenge in cancer treatment, impacting patient survival and prognosis. Understanding the biological mechanisms behind it is essential for improving treatment strategies and patient outcomes. Lung cancer, the leading cause of cancer-related deaths, is a focus of research for treatment and prognosis. This study specifically targets stage III non-small cell lung cancer (NSCLC) patients following surgery due to their high recurrence variability.
Methods:
To delve into the mechanisms of metastatic recurrence in stage III NSCLC patients, we used a comprehensive experimental approach. Long-term follow-up of postoperative patients was combined with single-cell sequencing to uncover tumor microenvironment changes. In vivo and in vitro experiments, including tissue cytometry analysis, real-time PCR, western blotting, gene silencing, cell co-culture, flow cytometry, and chromatin immunoprecipitation-quantitative PCR, were conducted to investigate ALCAM-related gene regulation. Tissue samples and clinical data were collected from stage III NSCLC patients who underwent lung cancer resection between August 2018 and July 2021.
Results:
Analysis revealed distinct epithelial gene expression patterns between recurrence and non-recurrence groups, highlighting the reduced interaction between ALCAM ligand on epithelial cells and CD6 receptor on T cells. Lower ALCAM levels intensified an immunosuppressive state, halting cell cycle progression and promoting tumor proliferation and migration, linked to metastatic recurrence. The transcription factor MYB was identified as a key ALCAM regulator, shedding light on its impact on tumor advancement. Reduced ALCAM expression correlated with poorer prognosis, offering insights into NSCLC recurrence mechanisms.
Conclusions:
Our study underscores the pivotal role of the ALCAM-CD6 axis in metastatic recurrence of stage III NSCLC. ALCAM regulation not only influences immune-tumor cell interactions but also drives tumor cell proliferation and migration by affecting the cell cycle. This finding presents a promising target for NSCLC treatment and aids in assessing patient prognosis effectively.
Insights
The ALCAM-CD6 axis is crucial in stage III non-small cell lung cancer (NSCLC) recurrence. Reduced ALCAM levels promote tumor growth and spread, offering new therapeutic targets and prognostic insights for NSCLC patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Metastatic recurrence is a major challenge in cancer treatment, particularly in lung cancer.
- Stage III non-small cell lung cancer (NSCLC) exhibits high recurrence variability, necessitating research into its underlying mechanisms.
Purpose of the Study:
- To investigate the biological mechanisms of metastatic recurrence in stage III NSCLC.
- To identify key molecular players and pathways involved in NSCLC progression and recurrence.
Main Methods:
- Comprehensive analysis of postoperative stage III NSCLC patients with long-term follow-up.
- Single-cell sequencing and in vivo/in vitro experiments to study tumor microenvironment and ALCAM-related gene regulation.
- Utilized tissue cytometry, PCR, western blotting, gene silencing, co-culture, flow cytometry, and ChIP-qPCR.
Main Results:
- Identified distinct epithelial gene expression patterns differentiating recurrence and non-recurrence groups.
- Discovered reduced ALCAM-CD6 interaction, leading to an immunosuppressive state, cell cycle arrest, and enhanced tumor proliferation and migration.
- MYB identified as a key regulator of ALCAM, with lower ALCAM correlating with poorer prognosis.
Conclusions:
- The ALCAM-CD6 axis plays a critical role in stage III NSCLC metastatic recurrence.
- ALCAM regulation impacts immune-tumor cell interactions, cell cycle, proliferation, and migration.
- This axis represents a promising therapeutic target and prognostic biomarker for NSCLC.
